KT A261
Alternative Names: KT-A261Latest Information Update: 16 Mar 2022
At a glance
- Originator Medical University of South Carolina
- Developer Kriya Therapeutics; Medical University of South Carolina
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Complement activation inhibitors; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Uveitis